A Study of Acalabrutinib and Vistusertib in Subjects with Relapsed/Refractory B-cell Malignancies

Trial Identifier: ACE-LY-110
Sponsor: AcertaPharma
NCTID:: NCT03205046
Start Date: June 2017
Primary Completion Date: November 2019
Study Completion Date: November 2019

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
United Kingdom Headington, United Kingdom, OX3 7LJ
United Kingdom London, United Kingdom, EC1A 7BE
United Kingdom Manchester, United Kingdom, M20 4BX
United Kingdom NOTTINGHAM, United Kingdom, NG5 1PB
United Kingdom Plymouth, United Kingdom, PL6 8DH
United Kingdom Sutton, United Kingdom, SM2 5PT
United States of America, CA La Jolla, CA, United States of America, 92093
United States of America, CA Los Angeles, CA, United States of America, 90095-1678
United States of America, KS Fairway, KS, United States of America, 66205
United States of America, MD Bethesda, MD, United States of America, 20892
United States of America, MN Rochester, MN, United States of America, 55902
United States of America, NE Omaha, NE, United States of America, 68198
United States of America, NJ Hackensack, NJ, United States of America, 07601
United States of America, OH Columbus, OH, United States of America, 43210
United States of America, TN Nashville, TN, United States of America, 37203
United States of America, TX Houston, TX, United States of America, 77030
United States of America, TX Tyler, TX, United States of America, 75702
United States of America, WA Seattle, WA, United States of America, 98104
United States of America, WA Seattle, WA, United States of America, 98109